T-adalafil CAS 171596-29-5 API Active Pharmaceutical Ingredient

Product Description:

Product Name: T-adalafil CAS NO: 171596-29-5

Synonyms:

(6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6] pyrido[3,4-b]indole-1,4-dione;

Cialis;

(6R,12aR)-6-(benzo[d][1,3]dioxol-5-yl)-2-methyl-2,3,12,12a tetrahydropyrazino [1',2':1,6] pyrido[3,4b] indole1,4(6H,7H)-dione;

Chemical & Physical Properties:

Appearance: Off-White crystalline solid

Assay :≥99.00%

Density: 1.51 g/cm3

Boiling Point: 679.1℃ at 760 mmHg

Melting Point: 298-300℃

Flash Point: 364.5℃

Refractive Index: 1.705

Vapor Pressure: 5.29E-13mmHg at 25℃

Safety Information:

Hazard Codes: F,Xn

Risk Statements: r11-20/21/22-36

Safety Statements: S16-36/37

WGK Germany: 3

RTECS: UQ4431050

HS Code: 2934990002

T-adalafil is a PDE5 inhibitor marketed in pill form for treating erectile dysfunction (ED) under the name Cialis, and under the name Adcirca for the treatment of pulmonary arterial hypertension. In October 2011 the U.S. Food and Drug Administration (FDA) approved Cialis for treating the signs and symptoms of benign prostatic hyperplasia (BPH) as well as a combination of BPH and erectile dysfunction (ED) when the conditions coincide. It initially was developed by the biotechnology company ICOS, and then again developed and marketed world-wide by Lilly ICOS, LLC, the joint venture of ICOS Corporation and Eli Lilly and Company. Cialis tablets, in 2.5mg, 5mg, 10mg, and 20mg doses, are yellow, film-coated, and almond-shaped. The approved dose for pulmonary arterial hypertension is 40mg (two 20-mg tablets) once daily.

T-adalafil is also manufactured and sold under the name of Tadacip by the Indian pharmaceutical company Cipla in doses of 10mg and 20mg.

On November 21, 2003 the FDA approved t-adalafil (as Cialis) for sale in the United States as the third ED prescription drug pill (after s-ildenafil citrate (V-iagra) and v-ardenafil Hydrochloride (Levitra)). Like s-ildenafil and v-ardenafil, t-adalafil is recommended as an 'as needed' medication. Cialis is the only one of the three that is also offered as a once-daily medication.

Moreover, t-adalafil was approved in May 2009 in the United States for the treatment of pulmonary arterial hypertension and is under regulatory review in other regions for this condition.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.